P-1207. In Vitro Activity of Zoliflodacin against Neisseria gonorrhoeae Isolates Collected in 2022 from The United States
Sarah M. McLeod(Innoviva (United States)), Alison Luckey(Global Antibiotic Research & Development Partnership), Meredith Hackel, C C Au(Global Antibiotic Research & Development Partnership)
Cited by 0
Related Papers
<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
|Antimicrobial Agents and Chemotherapy|2017|234
Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
|Antimicrobial Agents and Chemotherapy|2015|221
<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
|Antimicrobial Agents and Chemotherapy|2017|196
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
|International Journal of Antimicrobial Agents|2018|191
<i>In Vitro</i> Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015
|Antimicrobial Agents and Chemotherapy|2017|190